Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT01702194Phase 1Completed

TD-1211 IV/Oral Mass Balance Study

Role: lead

NCT01040637Phase 1Completed

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Role: lead

NCT01568411Phase 1Completed

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

Role: lead

NCT01459926Phase 2Completed

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

Role: lead

NCT01401985Phase 2Completed

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

Role: lead

NCT01655771Phase 1Completed

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Role: lead

NCT01333540Phase 2Completed

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Role: lead

All 7 trials loaded